Home >> Pharmaceuticals >> Food & Beverage >>

Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 27 | Code: MRS - 35163

Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Shanghai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shanghai Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Shanghai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Shanghai Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Shanghai Pharmaceutical Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Shanghai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Shanghai Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Shanghai Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Shanghai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shanghai Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Shanghai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Shanghai Pharmaceutical Co., Ltd. Snapshot 4
Shanghai Pharmaceutical Co., Ltd. Overview 4
Key Information 4
Key Facts 4
Shanghai Pharmaceutical Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Shanghai Pharmaceutical Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products Glance 9
Shanghai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Shanghai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Shanghai Pharmaceutical Co., Ltd. - Drug Profiles 12
Deuteporfin 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
thalidomide 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Hydroxytriptolide 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
LLTD-8 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Shanghai Pharmaceutical Co., Ltd. - Pipeline Analysis 17
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Target 17
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 18
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 19
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 20
Shanghai Pharmaceutical Co., Ltd. - Dormant Projects 21
Shanghai Pharmaceutical Co., Ltd. - Company Statement 22
Shanghai Pharmaceutical Co., Ltd. - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

List of Tables
Shanghai Pharmaceutical Co., Ltd., Key Information 4
Shanghai Pharmaceutical Co., Ltd., Key Facts 4
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015 6
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015 7
Shanghai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
Shanghai Pharmaceutical Co., Ltd. - Phase II, 2015 9
Shanghai Pharmaceutical Co., Ltd. - Phase I, 2015 10
Shanghai Pharmaceutical Co., Ltd. - Preclinical, 2015 11
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Target, 2015 17
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015 18
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015 19
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 20
Shanghai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015 21
Shanghai Pharmaceutical Co., Ltd., Other Locations 23
Shanghai Pharmaceutical Co., Ltd., Subsidiaries 23

List of Figures
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015 6
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015 7
Shanghai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015 17
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 18
Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 19
Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 20

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing